Risk Factors for Severe Bleeding Complications in Vitreoretinal Surgery and the Role of Antiplatelet or Anticoagulant Agents
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Ophthalmology Retina
- Vol. 5 (8) , e23-e29
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Perioperative risk of bleeding with antithrombotic agents in macular surgery: a national, prospective, multicentre studyActa Ophthalmologica, 2020
- Umgang mit gerinnungshemmenden Substanzen in der Ophthalmochirurgie – eine Umfrage unter Ophthalmochirurgen in DeutschlandDer Ophthalmologe, 2018
- Antiplatelets and anticoagulants in vitreoretinal surgery, with a special emphasis on novel anticoagulants: a national survey and reviewGraefe's Archive for Clinical and Experimental Ophthalmology, 2017
- Perioperative Bridging Anticoagulation in Patients with Atrial FibrillationNew England Journal of Medicine, 2015
- Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical ProceduresOtolaryngology–Head and Neck Surgery, 2015
- Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgeryBritish Journal of Ophthalmology, 2014
- Perioperative Management of Antithrombotic TherapyChest, 2012
- Antiplatelet and Anticoagulation Therapy in Vitreoretinal SurgeryAmerican Journal of Ophthalmology, 2011
- Warfarin in vitreoretinal surgery: a case controlled seriesBritish Journal of Ophthalmology, 2010
- The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgeryActa Ophthalmologica Scandinavica, 2003